MX2023004812A - Composiciones de polvo seco de profarmacos de treprostinil y metodos de uso de estos. - Google Patents
Composiciones de polvo seco de profarmacos de treprostinil y metodos de uso de estos.Info
- Publication number
- MX2023004812A MX2023004812A MX2023004812A MX2023004812A MX2023004812A MX 2023004812 A MX2023004812 A MX 2023004812A MX 2023004812 A MX2023004812 A MX 2023004812A MX 2023004812 A MX2023004812 A MX 2023004812A MX 2023004812 A MX2023004812 A MX 2023004812A
- Authority
- MX
- Mexico
- Prior art keywords
- dry powder
- methods
- powder compositions
- patient
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106818P | 2020-10-28 | 2020-10-28 | |
| PCT/US2021/057078 WO2022094100A1 (en) | 2020-10-28 | 2021-10-28 | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004812A true MX2023004812A (es) | 2023-07-06 |
Family
ID=81384296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004812A MX2023004812A (es) | 2020-10-28 | 2021-10-28 | Composiciones de polvo seco de profarmacos de treprostinil y metodos de uso de estos. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20240285570A1 (enExample) |
| EP (1) | EP4236934A4 (enExample) |
| JP (1) | JP7857292B2 (enExample) |
| KR (1) | KR20230096998A (enExample) |
| CN (1) | CN116437906B (enExample) |
| AU (1) | AU2021369679A1 (enExample) |
| CA (1) | CA3196252A1 (enExample) |
| MX (1) | MX2023004812A (enExample) |
| WO (1) | WO2022094100A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9469600B2 (en) | 2013-10-25 | 2016-10-18 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| CN119632930A (zh) * | 2019-04-29 | 2025-03-18 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| CN122514396A (zh) | 2023-10-30 | 2026-08-04 | 英斯梅德股份有限公司 | 药物递送装置、罩盖和药物递送方法 |
| AU2025206207A1 (en) * | 2024-01-04 | 2026-05-28 | Insmed Incorporated | Methods of treatment using dry powder compositions of treprostinil prodrugs |
| WO2025230917A1 (en) * | 2024-04-29 | 2025-11-06 | Pharmosa Biopharm Inc. | Methods for treating systemic sclerosis and frost bite by inhalation therapy |
| WO2026144627A1 (zh) * | 2024-12-31 | 2026-07-09 | 长风药业(美国)有限公司 | 一种曲前列环素衍生物的干粉组合物及其应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| IT1240750B (it) | 1990-04-12 | 1993-12-17 | Chiesi Farma Spa | Dispositivo per la somministrazione di sostanze medicamentose in polvere |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| JP2924924B2 (ja) | 1992-12-18 | 1999-07-26 | シェリング・コーポレーション | 粉末薬物のための吸入器 |
| GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
| SE9302550D0 (sv) | 1993-07-30 | 1993-07-30 | Ernst Hoerlin | Powder inhaler |
| PT101450B (pt) | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | Novo dispositivo para inalacao |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| FI95441C (fi) | 1994-05-31 | 1996-02-12 | Leiras Oy | Inhalointilaitteen lääkeainekammio |
| FR2725626A1 (fr) | 1994-10-18 | 1996-04-19 | Sofab | Dispositif pour l'inhalation de produits en poudre |
| SE9404439D0 (sv) | 1994-12-21 | 1994-12-21 | Astra Ab | Inhalation device |
| US6182655B1 (en) | 1995-12-07 | 2001-02-06 | Jago Research Ag | Inhaler for multiple dosed administration of a pharmacological dry powder |
| US5797392C1 (en) | 1996-01-22 | 2001-01-09 | Direct Haler As | Inhaler |
| US6026809A (en) | 1996-01-25 | 2000-02-22 | Microdose Technologies, Inc. | Inhalation device |
| US6001336A (en) | 1996-12-31 | 1999-12-14 | Inhale Therapeutic Systems | Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof |
| PT101988B (pt) | 1997-04-04 | 2004-02-27 | Hovione Farmaciencia Sa | Sistema de orientacao e posicionamento de um objecto |
| GB9805102D0 (en) | 1998-03-10 | 1998-05-06 | Ciba Geigy Ag | Device |
| US6257233B1 (en) | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
| ES2198922T3 (es) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | Particulas porosas grandes emitadas por un inhalador. |
| CA2341624C (en) | 1998-08-25 | 2008-12-02 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| IT1309592B1 (it) | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
| PT1158958E (pt) | 1999-03-05 | 2007-08-13 | Chiesi Farma Spa | ''composições farmacêuticas em pó, melhoradas, para inalação'' |
| ITMI991582A1 (it) | 1999-07-16 | 2001-01-16 | Chiesi Farma Spa | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
| WO2001068169A1 (en) | 2000-03-10 | 2001-09-20 | University Of North Carolina At Chapel Hill | Dry powder inhaler devices, multi-dose dry powder drug packages, control systems, and associated methods |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
| CN102697790A (zh) * | 2003-05-22 | 2012-10-03 | 联合治疗公司 | 化合物和释放前列环素类似物的方法 |
| EP1522325B1 (en) | 2003-10-06 | 2007-06-13 | Bang & Olufsen Medicom A/S | Inhaler |
| CA2678258A1 (en) * | 2007-02-09 | 2008-08-14 | United Therapeutics Corporation | Treprostinil treatment for interstitial lung disease and asthma |
| US8496002B2 (en) | 2007-06-12 | 2013-07-30 | Civitas Therapeutics, Inc. | Powder inhaler devices |
| US9469600B2 (en) * | 2013-10-25 | 2016-10-18 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| EP3452170A4 (en) * | 2016-05-05 | 2020-04-01 | Liquidia Technologies, Inc. | TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION |
| EP3554507A1 (en) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| CA3102967A1 (en) * | 2018-06-07 | 2019-12-12 | Mannkind Corporation | Composition and method for inhalation |
| CN119632930A (zh) * | 2019-04-29 | 2025-03-18 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| JP2023519199A (ja) * | 2020-03-25 | 2023-05-10 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグの医薬製剤及びその使用方法 |
-
2021
- 2021-10-28 CN CN202180072519.9A patent/CN116437906B/zh active Active
- 2021-10-28 US US18/034,619 patent/US20240285570A1/en active Pending
- 2021-10-28 CA CA3196252A patent/CA3196252A1/en active Pending
- 2021-10-28 MX MX2023004812A patent/MX2023004812A/es unknown
- 2021-10-28 JP JP2023526131A patent/JP7857292B2/ja active Active
- 2021-10-28 EP EP21887529.2A patent/EP4236934A4/en active Pending
- 2021-10-28 AU AU2021369679A patent/AU2021369679A1/en active Pending
- 2021-10-28 KR KR1020237013241A patent/KR20230096998A/ko active Pending
- 2021-10-28 WO PCT/US2021/057078 patent/WO2022094100A1/en not_active Ceased
-
2023
- 2023-11-17 US US18/513,377 patent/US20240122889A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116437906B (zh) | 2026-07-03 |
| JP7857292B2 (ja) | 2026-05-12 |
| US20240285570A1 (en) | 2024-08-29 |
| US20240122889A1 (en) | 2024-04-18 |
| KR20230096998A (ko) | 2023-06-30 |
| CA3196252A1 (en) | 2022-05-05 |
| AU2021369679A1 (en) | 2023-05-18 |
| WO2022094100A1 (en) | 2022-05-05 |
| EP4236934A1 (en) | 2023-09-06 |
| EP4236934A4 (en) | 2024-10-02 |
| JP2023548307A (ja) | 2023-11-16 |
| CN116437906A (zh) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001929A (es) | Composiciones de polvo seco de profarmacos de treprostinil y metodos de uso de las mismas. | |
| JP3701870B2 (ja) | 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニ | |
| CN110105200B (zh) | 用于治疗纤维化的经取代的芳族化合物及相关方法 | |
| JP2019528320A5 (enExample) | ||
| JP3204320B2 (ja) | あるシスチン誘導体の薬理学的使用 | |
| ES3008699T3 (en) | Stable ascorbic acid compositions and methods of using the same | |
| IL248745B (en) | (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza | |
| JP2023548307A5 (enExample) | ||
| ES2640474T3 (es) | Compuestos lipoílicos y su uso para el tratamiento de la lesión isquémica | |
| RU2018138195A (ru) | Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида | |
| KR100518066B1 (ko) | 우리딘 트리포스페이트 및 관련 화합물로 기관지염을 치료하는방법 | |
| JP2022530637A5 (enExample) | ||
| JP2012507552A (ja) | プロスタグラジンのアミノ酸塩 | |
| RU2010137337A (ru) | Способы и композиции для лечения респираторных заболеваний | |
| WO2021206833A3 (en) | Methods and compositions for treating tissue damage resulting from viral infections | |
| US20140023629A1 (en) | Ameliorating agent for chronic obstructive pulmonary disease | |
| JP2019123731A5 (enExample) | ||
| MX2025005154A (es) | Formulaciones orales compactables de ibutamoren. | |
| EP2265267B1 (en) | Compositions comprising n-halogenated or n, n-dihalogenated amine for treatment and prophylaxis of bronchopulmonary infections | |
| JP2022546703A (ja) | 耳鳴りの治療のためのオキシトシン組成物 | |
| RU2017142589A (ru) | Композиции и способы лечения или предупреждения легочной гипертензии | |
| JP2025505187A5 (enExample) | ||
| JP2024521808A (ja) | 呼吸窮迫を処置するための組成物及び方法 | |
| Black et al. | Streptomycin in tuberculous laryngitis | |
| US10385061B2 (en) | Medicarpin, its derivatives, manufacturing method thereof |